tbuckley/cabot-search huggingface dataset:
Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (“Ph-like” or “BCR-ABL1-Like”) Signature For Therapeutic Targeting and Clinical Intervention
Authors: Richard C. Harvey, Huining Kang, Kathryn G. Roberts, I-Ming L. Chen, Susan R. Atlas, Edward J. Bedrick, Julie M. Gastier-Foster, Jinghui Zhang, Daniela S. Gerhard, Malcolm A. Smith, Eric C. Larsen, Elizabeth A. Raetz, Naomi J. Winick, William L. Carroll, Eileen Stonerock, Nyla A. Heerema, Andrew J. Carroll, Shann-Ching Chen, Guangchun Song, Jared Becksfort, Michael Rusch, Yongjin Li, Jing Ma, Denise Ell, Shalini C. Reshmi, Mignon L. Loh, Meenakshi Davidas, Stephen P. Hunger, Charles G. Mullighan, Cheryl L. Willman
Journal: Blood (2013)
German hospital may face prosecution after publishing a research letter
Authors: Annette Tuffs
Journal: BMJ (2000)

A German university hospital is facing the threat of prosecution for negligent manslaughter after paediatricians from the hospital published a research letter in the Lancet (2000;356:310) reporting details of an outbreak of klebsiella infection in its neonatal intensive care unit.

The paediatricians and the hospital feel that they are being unjustly treated for their “clinical and scientific honesty” in writing up the case.

The outbreak at the University Hospital of Giessen lasted for two …
Abstract 2431: Quantification of in-vivo Matrix Metalloproteinase Activity and Myocardial Strain Yield Unique Spatial and Temporal Patterns in a Porcine Model of Myocardial Infarction
Authors: Zakir Sahul, James Song, Jarod McAteer, Donna Dione, Lawrence Dobrucki, Donald Dione, Xenophon Papademetris, Christi Hawley, Patti Cavaliere, Julie McLean, James Duncan, Francis Spinale, Albert J Sinusas
Journal: Circulation (2006)

Background: Activation of matrix metalloproteinases (MMPs) contribute to left ventricular (LV) remodeling post myocardial infarction (MI). Assessment of MMP activation has been limited to in-vitro ...
Abstract 4785: Comparison Of Long-term Clinical Outcomes Following Aortic Valve Replacement With Homografts And Porcine Stentless Valves
Authors: Ayyaz Ali, Amit Patel, Yasir Abu-Omar, Anila Mehta, Ziad Ali, Sabine Bleiziffer, Darren Freed, Ahmad Y Sheikh, Thanos Athanasiou, John Pepper
Journal: Circulation (2008)

The porcine stentless valve was designed to emulate the hemodynamic performance of the homograft. Early outcomes using either surgical option have been similar. However, long-term outcomes remain t...
Abstract 5008: Lifestyle Practices in Adults 65 Years and Older and 7-Year Follow-up Mortality: The Chicago Heart Association Detection Project in Industry Study (CHA)
Authors: Thanh Huyen T Vu, Daniel B Garside, Martha L Daviglus
Journal: Circulation (2008)

Background and Objective : Prospective data on combined effects of lifestyle practices (smoking, heavy drinking, and physical inactivity) in older age on mortality are limited. We examine the combined impact of lifestyle behaviors in adults 65 years and older on CVD, non-CVD, cancer, and all-cause mortality after 7 years of follow-up. Methods : In 1996, a health survey was mailed to all surviving participants, ages 65–102, from the Chicago Heart Association Detection Project in Industry Study. The response rate was 60% and the sample included 4,200 male and 3,288 female respondents. Unhealthy lifestyle (un-HL) practices were classified into three groups as having two or more , one , or none of the following three un-HL factors (current smoking or stopped smoking only within the past 10 years; heavy drinking -&gt;15 g/day for women or &gt;30 g/day for men; and infrequent exercise). Vital status was ascertained through 2003 via the National Death Index. Results : With adjustment for age, race, education, marital status, living arrangement, and BMI, the hazards of CVD, non-CVD, cancer, and all-cause mortality were highest among men and women who had two or more un-HL factors and lowest among those who had healthy lifestyle. For example, in men, compared to those with none un-HL factors, the hazard ratios (95%CIs) of all-cause death for those with two or more and one un-HL factors were 2.10 (1.73–2.46) and 1.56 (1.36–1.77), respectively. Associations were attenuated somewhat but remained strongly significant with further adjustment for comorbidities (see table ). Conclusion : Having no unhealthy lifestyle factors in older age is associated with a lower risk for CVD, non-CVD, cancer, and all-cause death. These results should encourage healthy lifestyle practices in elderly people to decrease mortality and promote longevity. Adjusted* Hazard Ratios (95% CIs) for CVD, Non-CVD, Cancer, and All-Cause Death by Number of Unhealthy Lifestyle Factors in 1996 and Gender
Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer
Authors: A. V. D’Amico, M.-H. Chen, M. C. Cox, W. Dahut, W. D. Figg
Journal: Journal of Clinical Oncology (2005)

4553 Purpose: We evaluated whether the time to return to the baseline prostate-specific antigen level (PSA response duration) was significantly associated with time to death following randomization for men with hormone refractory metastatic prostate cancer (HRMPC). Patients and Methods: The study (N = 213) and validation (N = 281) cohorts comprised 494 men with HRMPC treated on 4 prospective randomized phase II studies between 2/96 and 10/01. Cox regression was used to evaluate whether a significant association existed between the PSA response duration and the time to death following randomization controlling for treatment and known prognostic factors. For illustrative purposes, Kaplan Meier estimates of survival dichotomized about the median value of the PSA response duration from the study cohort were compared using a 2-sided log rank test for all men in the validation cohort whose PSA declined, and those with a PSA decline that was less than or at least 50%. Results: An increasing PSA response duration was significantly associated with a longer survival following randomization in the study (p = 0.001) and validation (p = 0.02) cohorts controlling for treatment and known prognostic factors as shown in the Table. The adjusted hazard ratio (AHR) for death was 1.9 [95% Confidence Interval (CI): 1.4, 2.6; p = 0.0002] for men in the study cohort with a PSA response duration that was less than the median value of 3 months as compared to 3 months or more. This AHR was 2.1 [95% CI: 1.2, 3.5; p = 0.01] for men in the validation cohort. Survival was significantly shorter for men in the validation cohort whose PSA response duration was less than as compared to at least the median value from the study cohort whether they experienced at least a 50% reduction (p = 0.05) in PSA or not (p = 0.03). Conclusion: The duration of the PSA response to treatment is significantly associated with the length of survival for men with HRMPC. No significant financial relationships to disclose.
Abstract 11296: Practice Level Variation in Cardiac Performance Measure Compliance: Insights from the American College of Cardiology's Practice Innovation and Clinical Excellence (PINNACLE) Program
Authors: Paul S Chan, Fengming Tang, Thomas M Maddox, John A Spertus
Journal: Circulation (2010)

Background: While the American College of Cardiology's Practice Innovation And Clinical Excellence (PINNACLE) Program has reported rates of compliance for performance measures for coronary artery d...
Abstract 9618: Bilateral Cardiac Sympathetic Denervation for Acute Management of Refractory Ventricular Arrhythmias
Authors: Olujimi A Ajijola, Nicholas Lellouche, Tara Bourke, Roderick Tung, Aman Mahajan, Kalyanam Shivkumar
Journal: Circulation (2011)

Background: Left cardiac sympathetic denervation (LCSD) suppresses ventricular arrhythmias (VAs), and reduces the incidence of sudden cardiac death (SCD). The role of bilateral cardiac sympathetic denervation (BCSD) remains unknown. The purpose of this study was to report the effects of BCSD in a small patient cohort. Methods: We reviewed records of 6 patients (5 males, age 47-75 years, 66.7% non-ischemic cardiomyopathy) who underwent BCSD to treat severe VAs refractory to all other treatment modalities. Reversible causes of VAs were addressed in all patients. All patients were on beta-blocker therapy, and at least one antiarrhythmic drug. Five patients underwent catheter mapping with endocardial and/or epicardial ablation to control VAs (mean 2.2±0.5 ablations/patient). VAs persisted in 3 patients despite prior LCSD. Surgical BCSD was successfully performed in all patients (50% simultaneously, 50% right cardiac sympathetic denervation after prior unsuccessful LCSD). Results: After BCSD, mean ICD shocks and anti-tachycardia pacing episodes (ATPs) decreased from 13.3±5.2 shocks and 26.8±12.6 ATPs to 0 shocks or ATPs in 3 patients, and decreased by over 50% in one patient. External shocks decreased from 11 to 0 in another patient. One patient showed no response to BCSD. All patients who responded to BCSD survived to hospital discharge. No major complications occurred in all patients. In three patients were not pacemaker-dependent, no significant changes in heart rate, PR, QRS, and corrected QT interval were noted. Conclusion: To our knowledge, this is the first reported cohort of patients to undergo BCSD. In these patients with electrical storm refractory to standard therapies, bilateral cardiac sympathetic denervation was safe and effective in acutely suppressing VAs, and preventing SCD.
Making the best of health advocates and interpreters
Authors: P. von Kaehne
Journal: BMJ (2002)

Patients have the right to know motivations of researchersEditor-Rao and Sant Cassia discussed the ethics of undisclosed payments to doctors recruiting patients in clinical trials. 1 For many years now the greater Glasgow community and primary care local research ethics committee has insisted that reference to doctors' payment is included in the patient information sheet that goes to all potential participants.I object to the payment being hidden behind such phrases as "your doctor's research fund will be paid," which a number of medical research ethics committees allow, and I note that the phrase "for the additional work involved" often appears.Although the NHS and NHS Scotland are the remit of two different parliaments, cross border acceptance of approval by medical research ethics committees exists.Patients are also likely to see the NHS as a whole and the ethical principles of doctors and other healthcare professionals as not having regional variations.In the interests of equality (as well as informed consent) British guidelines need to be developed on this and other minimum requirements of information to be given to patients.This could include the amount of payment.My quick, non-random survey of my non-medical family and friends shows that the size of the payment and the potential overall income are underestimated.Other types of personal gain exist for researchers that I also believe potential participants should know about-when the work forms part of the requirements for a degree.Some people who already have a professional qualification and who are using "their" patients in research do not always believe that it is necessary to inform patients that they are registered for a degree for which this research is necessary.Such research may not always reach publication and may be designed as a learning experience rather than a complete piece of research.If patients are to be expected to take part in research for altruistic reasons they have a right to know what reasons motivate the people carrying out the research.
Abstract P441: Racial Disparities in the Control Status of Cardiovascular Risk Factors in a Diabetic Underinsured Population
Authors: Yujie Wang, Peter T Katzmarzyk, Ronald Horswell, Wenhui Zhao, Wei Li, Jolene Johnson, Donna H Ryan, Gang Hu
Journal: Circulation (2013)

Background: The long term trends in control status of cardiovascular risk factors among type 2 diabetic patients is unclear. Aim: To investigate the race-specific trend in attainment of the America...
Specific Inhibition of Thrombin-Induced Cell Activation by the Neutrophil Proteinases Elastase, Cathepsin G, and Proteinase 3: Evidence for Distinct Cleavage Sites Within the Aminoterminal Domain of the Thrombin Receptor
Authors: Patricia Renesto, Mustapha Si-Tahar, Marc Moniatte, Viviane Balloy, Alain Van Dorsselaer, Dominique Pidard, Michel Chignard
Journal: Blood (1997)
Abstract 16454: Medication Adherence and Healthcare Utilization in Heart Failure
Authors: Sheila M McNallan, Shannon M Dunlay, Margaret M Redfield, Alanna M Chamberlain, Nilay D Shah, Susan A Weston, Amanda R Moraska, Veronique L Roger
Journal: Circulation (2011)

Objective: To determine among community patients with heart failure (HF), whether medication adherence is associated with risk of hospitalizations and emergency department (ED) visits, independentl...
A review of the depressive personality
Authors: K A Phillips, J G Gunderson, R M Hirschfeld, L E Smith
Journal: American Journal of Psychiatry (1990)

A depressive type of personality disorder has been described by both German phenomenologists and psychoanalysts and has been used by clinicians for years. Although this personality type has been included in standard international nosologic systems (ICD-9), it has never been recognized in DSM. This literature review identifies and explores the issues relevant to the possible inclusion of such a category--an axis II personality disorder linked to axis I depressive disorder--in the upcoming DSM-IV.
Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study
Authors: McCann Ud, Agras Ws
Journal: American Journal of Psychiatry (1990)

Twenty-three women with nonpurging bulimia underwent a 12-week, double-blind, placebo-controlled trial of desipramine hydrochloride. Repeated standardized rating scales, mood assessments, and self-reports of dietary habits were used to measure changes in binge frequency and cognitive processes associated with food intake. The women who received desipramine reduced their frequency of binge eating by 63%, but women receiving placebo increased their frequency of binge eating by 16%. Twelve weeks after initiating treatment, 60% of the treatment group but only 15% of the placebo group abstained from binge eating. The women who received desipramine showed significantly more dietary restraint and reported significantly less hunger, suggesting that desipramine acts to suppress appetite. These preliminary findings suggest that the therapeutic effects of desipramine established in the treatment of purging bulimia nervosa extend to patients with nonpurging bulimia.
Abstract 15665: Ablation of Nkx2-5 Beginning at Mid-Embryonic Stage Results in Premature Lethality and Cardiac Malformation
Authors: Ryota Terada, Sonisha Warren, Andy Wessels, Kenneth R Chien, Hideko Kasahara
Journal: Circulation (2010)

Background:  Human congenital heart disease linked to mutations in NKX2-5 is characterized by cardiac anomalies (atrial and/or ventricular septal defects and tetralogy of Fallot), and conduction and contraction defects. In mice, homozygous germline deletion of Nkx2-5 gene results in lethality at E10.5. Whether Nkx2-5 is necessary for cardiac development beyond this embryonic stage is not well understood.   Methods and Results:  We utilized tamoxifen-inducible Nkx2-5 knockout mice that carry homozygous floxed-Nkx2-5 alleles and a heterozygous Cre-ERTM transgene under the control of CMV enhancer and chicken-β-globin promoter. Tamoxifen injection into pregnant mice on gestational day 12.5 nearly completely deleted Nkx2-5 genes in the embryos demonstrated by quantitative RT-PCR and Western blotting. Nkx2-5-ablated embryos (n=13) demonstrated arrhythmias and contraction abnormalities at E16.5 by echocardiogram in utero and died by E17.5, which was not observed in control embryos after tamoxien-injection (flox/flox, n=8 or wild/wild/Cre, n=3). Nkx2-5 ablated hearts demonstrated markedly thinner outer compact layers and cardiac anomalies including atrial and/or ventricular septal defects. Quantitative serial section histology revealed growth retardation of the septum secundum from the atrial myocardium in Nkx2-5 ablated embryos [flox/flox 94 μm (n=3) vs. flox/flox/Cre 46 μm (n=5)], which partly explains the cardiac anomalies. Cardiac transcript levels of cardiac voltage-gated Na+ channel pore-forming α-subunit (Nav1.5-α), KcneI/minK and gap junction protein connexin40 were reduced greater than 70% within 4 days after tamoxifen-injection.   Conclusions:  Because a previous study demonstrated no cardiac anomalies in mice with ventricular-restricted deletion of Nkx2-5, the observed embryonic lethality and septum anomalies are likely due to near complete deletion of Nkx2-5 in the entire heart. Reduction in target gene expression may contribute to the cardiac phenotype demonstrated in embryos with Nkx2-5 ablation beginning at E12.5. Our results provide evidence that Nkx2-5 is necessary for survival of embryos after the mid-embryonic stage for maintenance of cardiac function and formation by regulation of expression of its target genes.
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group
Authors: WG Woods, N Kobrinsky, JD Buckley, JW Lee, J Sanders, S Neudorf, S Gold, DR Barnard, J DeSwarte, K Dusenbery, D Kalousek, DC Arthur, BJ Lange
Journal: Blood (1996)
Abstract 16190: Clinical Factors and Management of Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis
Authors: Kengo Kusano, Shiro Kamakura, Shin-Ichiro Morimoto
Journal: Circulation (2011)

(Background) Sarcoidosis is a systemic inflammatory syndrome of unknown etiology and cardiac involvement (heart failure, AV block and ventricular arrhythmias) has been reported to be an important p...
Dietary Regimens for Atopic Dermatitis in Childhood
Authors: T J David, Leena Patel, Carol I Ewing, R H J Stanton
Journal: Journal of the Royal Society of Medicine (1997)

Double-blind placebo-controlled food challenges (DBPCFC) in selected children with atopic dermatitis have clearly shown that some of these children have allergic reactions to food. Sampson, for example, administered selected foods in doses of 8 g or less, and in sensitive subjects this provoked an immediate (within 2 h) itchy erythematous macular rash, accompanied by a significant rise in the plasma histamine concentrationl-3. It is known that atopic dermatitis can worsen following exposure to allergic (e.g. foods, pet animals) or non-allergic (e.g. heat, skin contact with wool) triggers. The question arises as to whether these triggers cause dermatitis or simply worsen pre-existing dermatitis. The role of food allergy in the pathogenesis of atopic dermatitis is discussed by Sampson on page 2 in this supplement. The present review focuses on the different dietary approaches to the management of atopic dermatitis in childhood.
Abstract 2511: Impact of Olmesartan on Progression of Coronary Atherosclerosis; - A Serial Volumetric IVUS Analysis from the OLIVUS Trial -
Authors: Atsushi Hirohata, Hirosuke Yamaji, Masaaki Murakami, Eiki Hirose, Keisuke Ohkawa, Makoto Ishizawa, Shinji Sato, Tadashi Morota, Tohru Miyoshi, Kunihiko Hatanaka, Hitoshi Yamawaki, Issei Komatsubara, Keizo Yamamoto
Journal: Circulation (2008)

Prior intravascular ultrasound (IVUS) trials suggest slowing of coronary plaque progression with some medicines but have not shown convincing evidence of regression using angiotension-II receptor blocking agents (ARB). A prospective, double-blind, randomized, multicenter trial (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound [OLIVUS]) was performed in 247 stable angina pectoris patients with native coronary artery lesions. When these patients underwent percutaneous coronary intervention for culprit lesions, IVUS was performed in their non-culprit vessels (without angiographically documented coronary stenosis [&lt;50%]). Patients were randomly assigned to receive 20 mg of Olmesartan or control, and treated with a combination of β-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents and/or statins per physician’s guidance. Patients already on ACE inhibitors or other ARBs were excluded. Serial IVUS examinations (baseline and 14-months follow-up) were performed to assess coronary plaque volume. Volumetric IVUS analyses (mean measured length:41.2 ± 8.7mm) included lumen (LV), plaque (PV), vessel volume (VV), percent plaque volume (% PV), percent change in total PV (PCPV) and percent change in % PV (PC%PV). At baseline, patient characteristics and all IVUS parameters were identical between the two groups. However, follow-up IVUS showed significantly decreased PCPV and PC%PV in the Olmesartan group, despite similar blood pressure (table ). In addition, multivariate analysis identified Olmesartan administration as one of the factors that decreased plaque volume (β-coefficient −0.29 (95%CI, −0.7 to 0.4), p&lt;0.01). These observations suggest a positive role in potential plaque regression through the administration of Olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.
Soundings: Facilitators and guidelines
Authors: Kevin Barraclough
Journal: BMJ (2002)

She beamed at us enthusiastically across the table. My partners had not yet settled and the room was restless with the Monday lunchtime tension born of expectant patients and inadequate resources.

“I'm your new dementia facilitator,” she said. “I'm developing some new guidelines for you.” She paused dramatically. “And a toolkit.” I imagined some sort of adjustable wrench that would fix dementia. “And the audit?” one of my partners asked. “Is coming later,” our facilitator assured us earnestly. My colleague nodded weakly. “Good,” he said. “Good.”

I gather that this lady used to see patients and was very good at it. Then she became a facilitator. I don't remember having these facilitators around before. They seem to be a new life form, mutated in the starkly unstable environment of the NHS from something useful like a nurse.

The NHS is now full of opportunities if you don't want to see patients. In the old days, unless you were a professor of medicine or surgery or whatever, pretty much all you could do was see patients. Now the NHS is much more egalitarian. We can all become facilitators, advisers, liaison people, appraisers, trust managers, performance leads, guideline gurus, and so on. In fact, it is now quite easy to avoid ever seeing a patient at all. Which is nice because not everyone wants to see patients. In fact, it seems as if hardly anyone wants to see them.

I used to do guidelines. I did one a few years ago for secondary prevention of coronary artery disease and in a month it was out of date. So I did one on heart failure and that lasted over two months. The nice thing about writing guidelines yourself is that you know what is in them. I thought guidelines were great—until people started doing them to me. I'm a bit “guidelined out” now. They hit me from every direction like confetti, but often with the added ballast of yet another audit. Each one usually has a mission statement so vacuous as to be entirely without content—“It is our aim to promote and facilitate patient care.” This is, I suppose, in case you might misunderstand and think that their aim is to demote and obstruct patient care. Still, now I come to think of it, maybe they do need to state it.
Abstract 17831: Transplantation of Human Pericyte Progenitor Cells Enhances Reparative Arteriogenesis and Attenuates Ventricular Dysfunction in a Mouse Model of Myocardial Infarction
Authors: Rajesh Katare, Paola Campagnolo, Giuseppe Mangialardi, Kathryn Mitchell, Costanza Emanueli, Paolo Madeddu
Journal: Circulation (2010)

Objective: Clinical evidence indicates that transplantation of heterogeneous cell populations helps the healing of infarcted heart by various ways including paracrine promotion of angiogenesis. To ...